HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
HeartSciences (Nasdaq: HSCS) announced that CEO Andrew Simpson will present at the Emerging Growth Conference 82 on Wednesday, May 21, 2025 at 10:15 AM EDT. The virtual presentation will include a live Q&A session, providing investors insight into the company's AI-ECG platform and mission.
HeartSciences specializes in AI-powered medical technology focused on transforming ECGs/EKGs for earlier heart disease detection. The presentation will highlight their AI-ECG platform, designed to enhance standard ECG diagnostic capabilities at the point of care. Simpson will also discuss a current Regulation A investment opportunity available to qualified investors.
HeartSciences (Nasdaq: HSCS) ha annunciato che il CEO Andrew Simpson presenterà al Emerging Growth Conference 82 mercoledì 21 maggio 2025 alle 10:15 EDT. La presentazione virtuale includerà una sessione di domande e risposte in diretta, offrendo agli investitori una panoramica sulla piattaforma AI-ECG e sulla missione dell'azienda.
HeartSciences è specializzata in tecnologia medica basata sull'intelligenza artificiale, focalizzata sulla trasformazione degli ECG per una diagnosi precoce delle malattie cardiache. La presentazione metterà in evidenza la loro piattaforma AI-ECG, progettata per migliorare le capacità diagnostiche degli ECG standard direttamente al punto di cura. Simpson parlerà anche di un'opportunità di investimento attuale sotto la Regulation A, riservata agli investitori qualificati.
HeartSciences (Nasdaq: HSCS) anunció que el CEO Andrew Simpson presentará en la Emerging Growth Conference 82 el miércoles 21 de mayo de 2025 a las 10:15 AM EDT. La presentación virtual incluirá una sesión de preguntas y respuestas en vivo, brindando a los inversores una visión sobre la plataforma AI-ECG y la misión de la empresa.
HeartSciences se especializa en tecnología médica impulsada por inteligencia artificial, enfocada en transformar los ECG para una detección temprana de enfermedades cardíacas. La presentación destacará su plataforma AI-ECG, diseñada para mejorar las capacidades diagnósticas estándar del ECG en el punto de atención. Simpson también hablará sobre una oportunidad de inversión actual bajo la Regulation A disponible para inversores calificados.
HeartSciences (나스닥: HSCS)의 CEO 앤드류 심슨이 Emerging Growth Conference 82에서 2025년 5월 21일 수요일 오전 10시 15분(EDT)에 발표할 예정이라고 발표했습니다. 이번 온라인 발표에는 실시간 질의응답 세션이 포함되어 투자자들에게 회사의 AI-ECG 플랫폼과 미션에 대한 통찰을 제공합니다.
HeartSciences는 심장 질환 조기 발견을 위한 ECG 변환에 중점을 둔 AI 기반 의료 기술을 전문으로 합니다. 이번 발표에서는 현장 진료 시 표준 ECG 진단 기능을 향상시키기 위해 설계된 AI-ECG 플랫폼을 소개할 예정입니다. 심슨 CEO는 자격을 갖춘 투자자를 위한 현재 Regulation A 투자 기회에 대해서도 논의할 것입니다.
HeartSciences (Nasdaq : HSCS) a annoncé que le PDG Andrew Simpson présentera lors de la Emerging Growth Conference 82 le mercredi 21 mai 2025 à 10h15 EDT. La présentation virtuelle comprendra une session de questions-réponses en direct, offrant aux investisseurs un aperçu de la plateforme AI-ECG et de la mission de l’entreprise.
HeartSciences est spécialisée dans la technologie médicale alimentée par l’IA, axée sur la transformation des ECG pour une détection précoce des maladies cardiaques. La présentation mettra en lumière leur plateforme AI-ECG, conçue pour améliorer les capacités de diagnostic des ECG standards au point de soin. Simpson abordera également une opportunité d’investissement actuelle selon la Regulation A, disponible pour les investisseurs qualifiés.
HeartSciences (Nasdaq: HSCS) gab bekannt, dass CEO Andrew Simpson am Emerging Growth Conference 82 am Mittwoch, den 21. Mai 2025, um 10:15 Uhr EDT präsentieren wird. Die virtuelle Präsentation beinhaltet eine Live-Fragerunde, die Investoren Einblicke in die AI-ECG-Plattform und die Mission des Unternehmens bietet.
HeartSciences spezialisiert sich auf KI-gestützte Medizintechnologie, die darauf abzielt, EKGs für eine frühere Erkennung von Herzkrankheiten zu transformieren. Die Präsentation wird ihre AI-ECG-Plattform hervorheben, die darauf ausgelegt ist, die diagnostischen Fähigkeiten herkömmlicher EKGs direkt am Behandlungsort zu verbessern. Simpson wird auch eine aktuelle Regulation A-Investitionsmöglichkeit für qualifizierte Investoren erläutern.
- None.
- None.
Southlake, TX, May 20, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson will deliver a live presentation and participate in a Q&A session at the Emerging Growth Conference 82.
Event Details:
Date: Wednesday, May 21, 2025
Time: 10:15 AM EDT | 7:15 AM PDT
Format: Virtual presentation with live Q&A
Registration
To attend this live, interactive online event, please register though: Emerging Growth Conference 82
This event provides investors with an opportunity to gain insight into HeartSciences’ mission, market opportunity, and its AI-ECG platform, which is designed to significantly enhance the diagnostic utility of the standard ECG. The platform aims to help clinicians detect heart disease earlier, faster, and at the point of care. CEO Andrew Simpson will also discuss the Company’s current Regulation A investment opportunity, which offers qualified investors access to investment in the Company on terms typically not available through public markets.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on Emerging Growth and on the Emerging Growth YouTube Channel, Emerging Growth Conference. We will release a link to that after the event.
About HeartSciences
HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 29, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2024, filed with the SEC on September 12, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024, filed with the SEC on December 16, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2025, filed with the SEC on March 13, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski
Partner
Phone: 877-255-8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
Phone: +1-682-244-2578 Ext. 2024
Email: info@heartsciences.com
FAQ
When is HeartSciences (HSCS) presenting at the Emerging Growth Conference 82?
What will HeartSciences (HSCS) discuss at the Emerging Growth Conference?
What is HeartSciences' (HSCS) main technology focus?
How can investors attend HeartSciences' (HSCS) presentation at the Emerging Growth Conference?
